WO2006048745A1 - Methodes de preparation de composes d'indazole - Google Patents
Methodes de preparation de composes d'indazole Download PDFInfo
- Publication number
- WO2006048745A1 WO2006048745A1 PCT/IB2005/003300 IB2005003300W WO2006048745A1 WO 2006048745 A1 WO2006048745 A1 WO 2006048745A1 IB 2005003300 W IB2005003300 W IB 2005003300W WO 2006048745 A1 WO2006048745 A1 WO 2006048745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- alkyl
- aryl
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000012453 solvate Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 108
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
- -1 -OH Chemical group 0.000 claims description 62
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 239000003054 catalyst Substances 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000006239 protecting group Chemical group 0.000 claims description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 21
- 239000002585 base Substances 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 229910052763 palladium Inorganic materials 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 239000012954 diazonium Substances 0.000 claims description 16
- 150000001989 diazonium salts Chemical class 0.000 claims description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical group [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 14
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 13
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical group [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 7
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 235000010288 sodium nitrite Nutrition 0.000 claims description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001805 chlorine compounds Chemical group 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000004694 iodide salts Chemical group 0.000 claims description 5
- 229910001507 metal halide Inorganic materials 0.000 claims description 5
- 150000005309 metal halides Chemical class 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 claims description 3
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 abstract description 9
- 108060006633 protein kinase Proteins 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 98
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- 229910001868 water Inorganic materials 0.000 description 50
- 239000000243 solution Substances 0.000 description 43
- 239000007787 solid Substances 0.000 description 39
- 235000019439 ethyl acetate Nutrition 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 229920002554 vinyl polymer Polymers 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000008096 xylene Substances 0.000 description 12
- 150000003738 xylenes Chemical class 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000012467 final product Substances 0.000 description 11
- 150000004820 halides Chemical class 0.000 description 11
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 235000011181 potassium carbonates Nutrition 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 8
- 238000007341 Heck reaction Methods 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- VIFOAZNEQRHREM-UHFFFAOYSA-N n-methyl-2-sulfanylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1S VIFOAZNEQRHREM-UHFFFAOYSA-N 0.000 description 7
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- BLNITUQUAUXMJG-UHFFFAOYSA-N 3-iodo-6-nitro-1-(oxan-2-yl)indazole Chemical compound C12=CC([N+](=O)[O-])=CC=C2C(I)=NN1C1CCCCO1 BLNITUQUAUXMJG-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 150000004292 cyclic ethers Chemical class 0.000 description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 6
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 5
- GZCGNGLOCQEDMT-UHFFFAOYSA-N 3-iodo-6-nitro-2h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C(I)=NNC2=C1 GZCGNGLOCQEDMT-UHFFFAOYSA-N 0.000 description 5
- ORZRMRUXSPNQQL-UHFFFAOYSA-N 6-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C=NNC2=C1 ORZRMRUXSPNQQL-UHFFFAOYSA-N 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 239000002841 Lewis acid Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 150000005215 alkyl ethers Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940113088 dimethylacetamide Drugs 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 150000007517 lewis acids Chemical class 0.000 description 5
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 235000011118 potassium hydroxide Nutrition 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- LBEMXJWGHIEXRA-UHFFFAOYSA-N 2-[(2-carboxyphenyl)disulfanyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(O)=O LBEMXJWGHIEXRA-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 150000007860 aryl ester derivatives Chemical class 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 229940011051 isopropyl acetate Drugs 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NSPUYMWXWXSVAJ-CSKARUKUSA-N 1-(oxan-2-yl)-3-[(e)-2-pyridin-2-ylethenyl]indazol-6-amine Chemical compound N=1N(C2OCCCC2)C2=CC(N)=CC=C2C=1\C=C\C1=CC=CC=N1 NSPUYMWXWXSVAJ-CSKARUKUSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000004983 alkyl aryl ketones Chemical class 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000008378 aryl ethers Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 3
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 3
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 150000003003 phosphines Chemical class 0.000 description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 0 *c1n[n]c2c1ccc(Sc1c(*)ccc(*)c1C(N*)=O)c2 Chemical compound *c1n[n]c2c1ccc(Sc1c(*)ccc(*)c1C(N*)=O)c2 0.000 description 2
- NHUBNHMFXQNNMV-UHFFFAOYSA-N 2-ethynylpyridine Chemical compound C#CC1=CC=CC=N1 NHUBNHMFXQNNMV-UHFFFAOYSA-N 0.000 description 2
- XHVJIWVECAQYNF-UHFFFAOYSA-N 3,6-diiodo-2h-indazole Chemical compound IC1=CC=C2C(I)=NNC2=C1 XHVJIWVECAQYNF-UHFFFAOYSA-N 0.000 description 2
- RSGAXJZKQDNFEP-UHFFFAOYSA-N 6-iodo-1h-indazole Chemical compound IC1=CC=C2C=NNC2=C1 RSGAXJZKQDNFEP-UHFFFAOYSA-N 0.000 description 2
- BKXMYFOISYYOLE-JXMROGBWSA-N 6-nitro-1-(oxan-2-yl)-3-[(e)-2-pyridin-2-ylethenyl]indazole Chemical compound N=1N(C2OCCCC2)C2=CC([N+](=O)[O-])=CC=C2C=1\C=C\C1=CC=CC=N1 BKXMYFOISYYOLE-JXMROGBWSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- XEFCWBLINXJUIV-UHFFFAOYSA-N acetic acid;iodobenzene Chemical compound CC(O)=O.CC(O)=O.IC1=CC=CC=C1 XEFCWBLINXJUIV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 150000004673 fluoride salts Chemical class 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UTPQCFJFGGRKPB-UHFFFAOYSA-N n-methyl-2-[[3-(2-pyridin-2-ylethynyl)-2h-indazol-6-yl]sulfanyl]benzamide Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(=NN2)C#CC=3N=CC=CC=3)C2=C1 UTPQCFJFGGRKPB-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000005490 tosylate group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000002348 vinylic group Chemical group 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical class NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 1
- QMQZIXCNLUPEIN-UHFFFAOYSA-N 1h-imidazole-2-carbonitrile Chemical group N#CC1=NC=CN1 QMQZIXCNLUPEIN-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- GSCCALZHGUWNJW-UHFFFAOYSA-N N-Cyclohexyl-N-methylcyclohexanamine Chemical compound C1CCCCC1N(C)C1CCCCC1 GSCCALZHGUWNJW-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001343 alkyl silanes Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000001503 aryl iodides Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- UYANAUSDHIFLFQ-UHFFFAOYSA-N borinic acid Chemical compound OB UYANAUSDHIFLFQ-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- ABQPEYRVNHDPIO-UHFFFAOYSA-N bromo(dimethyl)borane Chemical compound CB(C)Br ABQPEYRVNHDPIO-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical class Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- BTVWZWFKMIUSGS-UHFFFAOYSA-N dimethylethyleneglycol Natural products CC(C)(O)CO BTVWZWFKMIUSGS-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910001506 inorganic fluoride Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MOVBJUGHBJJKOW-UHFFFAOYSA-N methyl 2-amino-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1N MOVBJUGHBJJKOW-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- SEOYNUHKXVGWFU-UHFFFAOYSA-N mu-oxidobis(oxidonitrogen) Chemical compound O=NON=O SEOYNUHKXVGWFU-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IYRGXJIJGHOCFS-UHFFFAOYSA-N neocuproine Chemical compound C1=C(C)N=C2C3=NC(C)=CC=C3C=CC2=C1 IYRGXJIJGHOCFS-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical class [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- ZGJADVGJIVEEGF-UHFFFAOYSA-M potassium;phenoxide Chemical compound [K+].[O-]C1=CC=CC=C1 ZGJADVGJIVEEGF-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QSUJAUYJBJRLKV-UHFFFAOYSA-M tetraethylazanium;fluoride Chemical compound [F-].CC[N+](CC)(CC)CC QSUJAUYJBJRLKV-UHFFFAOYSA-M 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- POSYVRHKTFDJTR-UHFFFAOYSA-M tetrapropylazanium;fluoride Chemical compound [F-].CCC[N+](CCC)(CCC)CCC POSYVRHKTFDJTR-UHFFFAOYSA-M 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910006384 μ-Br Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to methods for preparing indazole compounds, and intermediates thereof, which are useful as modulators and/or inhibitors of protein kinases.
- U.S. Patent Nos. 6,531 ,491 and 6,534,524 are directed to indazole compounds that modulate and/or inhibit the activity of certain protein kinases such as VEGF-R (vascular endothelial cell growth factor receptor), FGF-R (fibroblast growth factor receptor), CDK (cyclin-dependent kinase) complexes,
- VEGF-R vascular endothelial cell growth factor receptor
- FGF-R fibroblast growth factor receptor
- CDK cyclin-dependent kinase
- CHK1 also known as lymphocyte-specific tyrosine kinase
- TEK also known as Tie-2
- FAK focal adhesion kinase
- phosphorylase kinase Such compounds are useful for the treatment of cancer and other diseases associated with angiogenesis or cellular proliferation mediated by protein kinases.
- R 10 is independently selected from hydrogen, halogen, and lower-alkyl; and pharmaceutically acceptable prodrugs, pharmaceutically acceptable metabolites, and pharmaceutically acceptable salts thereof.
- the invention relates to methods for preparing a compound of formula I:
- R 4 is (C 1 to C 12 ) alkyl, (C 3 to C 12 ) cycloalkyl, (5 to 12-membered) heterocycloalkyl, (C 6 to C 12 ) aryl, or (5 to 12-membered) heteroaryl, and R 4 is substituted with 0 to 4 R 5 groups; each R 5 is independently halogen, (C 1 to C 8 ) alkyl, (C 2 to C 8 ) alkenyl, (C 2 to C 8 ) alkynyl, -OH, -NO 2 , -CN, -CO 2 H, -0(C 1 to C 8 alkyl), (C 6 to C 12 ) aryl, (C 6 to C 12 ) aryl (C 1 to C 8 ) alkyl, -CO 2 CH 3 , -CONH 2 , -OCH 2 CONH 2 , -NH 2 , -SO 2 NH 2 , halo substituted (C 1 to C 12 ) alky
- Il III IV wherein the reaction occurs in the presence of a catalyst and a base; W is a protecting group; X is an activated substituent group; and R 1 , R 2 , and R 3 are as described above; and b) deprotecting the compound of formula IV to provide the compound of formula I.
- the invention relates to method for preparing a compound of formula I, wherein the catalyst is a palladium catalyst. In another aspect, the invention relates to methods for preparing a compound of formula
- the invention relates to methods for preparing a compound of formula I, wherein the base is selected from the group consisting of potassium carbonate, sodium carbonate, cesium carbonate, sodium t-butoxide, potassium t-butoxide, triethylamine, and mixtures thereof.
- the invention relates to methods for preparing a compound of formula I, wherein the base is cesium carbonate.
- the invention relates to methods for preparing a compound of formula I, further comprising a solvent in the reaction between the compound of formula Il and the compound of formula III.
- the invention relates to methods for preparing a compound of formula I, wherein the solvent is N, N-dimethyl formamide.
- the invention relates to methods for preparing a compound of formula I, wherein the reaction is carried out at about 80°C. In another aspect, the invention relates to methods for preparing a compound of formula
- W is a tetrahydropyran protecting group or a trimethylsilylethoxymethyl protecting group.
- the invention relates to methods for preparing a compound of formula I, wherein the activated substituent group X is chloride, bromide, or iodide. In another aspect, the invention relates to methods for preparing a compound of formula
- the invention relates to methods for preparing a compound of formula I, wherein the protecting group W is tetrahydropyran, and the process of deprotecting comprises reacting the compound of formula IV with an acid in an alcoholic solvent.
- the invention relates to methods for preparing a compound of formula
- the acid is methanesulfonic acid or is p-toluenesulfonic acid
- the alcoholic solvent is methanol, ethanol, n-propanol or isopropanol.
- the invention relates to methods for preparing a compound of formula I, wherein the compound of formula Il has formula V, and the compound of formula III has formula Vl:
- the invention relates to methods for preparing a compound of formula I, wherein the compound of formula IV has formula VII:
- the invention relates to methods for preparing a compound of formula I, wherein the compound of formula I has formula VIII:
- the invention relates to methods for preparing a compound of formula
- R 4 is (C 1 to C 12 ) alkyl, (C 3 to C 12 ) cycloalkyl, (5 to 12-membered) heterocycloalkyl, (C 6 to C 12 ) aryl, or (5 to 12-membered) heteroaryl, and R 4 is substituted with 0 to 4 R 5 groups; each R 5 is independently halogen, (C 1 to C 8 ) alkyl, (C 2 to C 8 ) alkenyl, (C 2 to C 8 ) alkynyl, -OH, -NO 2 , -CN, -CO 2 H, -0(C 1 to C 8 alkyl), (C 6 to C 12 ) aryl, (C 6 to C 12 ) aryl (C 1 to C 8 ) alkyl,
- W is a protecting group; and X is an activated substituent group; comprising: a) reacting a compound of formula IX with a diazotizing agent to form a diazonium salt; and b) treating the diazonium salt with a metal halide,
- the invention relates to methods for preparing a compound of formula II, wherein the activated substituent group X is iodide.
- the invention relates to methods for preparing a compound of formula II, wherein the diazotizing agent is sodium nitrite or t-butyl nitrite.
- the invention relates to methods for preparing a compound of formula II, wherein the diazotizing agent is sodium nitrite, and the metal halide is potassium iodide.
- the invention relates to methods for preparing a compound of formula II, further comprising a catalytic amount of iodine. In another aspect, the invention relates to methods for preparing a compound of formula
- ⁇ T- is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.
- substituents it is meant to indicate that the group in question may optionally be substituted by one or more of the substituents provided.
- the number of substituents a group in the compounds of the invention may have depends on the number of positions available for substitution. For example, an aryl ring in the compounds of the invention may contain from 1 to 5 additional substituents, depending on the degree of substitution present on the ring. The maximum number of substituents that a group in the compounds of the invention may have can be easily determined.
- react refers to a chemical process or processes in which two or more reactants are allowed to come into contact with each other to effect a chemical change or transformation. For example, when reactant A and reactant B are allowed to come into contact with each other to afford a new chemical compound(s) C, A is said to have “reacted” with B to produce C.
- protect refers to a process in which a functional group in a chemical compound is selectively masked by a non-reactive functional group in order to allow a selective reaction(s) to occur elsewhere on said chemical compound.
- non-reactive functional groups are herein termed "protecting groups.”
- nitrogen protecting group refers to those groups that are capable of selectively masking the reactivity of a nitrogen (N) group.
- suitable protecting group refers to those protecting groups that are useful in the preparation of the compounds of the present invention. Such groups are generally able to be selectively introduced and removed using mild reaction conditions that do not interfere with other portions of the subject compounds.
- Protecting groups that are suitable for use in the processes and methods of the present invention are well known. The chemical properties of such protecting groups, methods for their introduction and their removal can be found, for example, in T. Greene and P.
- leaving group refers to a chemical functional group that generally allows a nucleophilic substitution reaction to take place at the atom to which it is attached.
- the -Cl group is generally referred to as a leaving group because it allows nucleophilic substitution reactions to take place at the carbonyl carbon.
- Suitable leaving groups are well known, and can include halides, aromatic heterocycles, cyano, amino groups (generally under acidic conditions), ammonium groups, alkoxide groups, carbonate groups, formates, and hydroxy groups that have been activated by reaction with compounds such as carbodiimides.
- suitable leaving groups include, but are not limited to, chloride, bromide, iodide, cyano, imidazole, and hydroxy groups that have been allowed to react with a carbodiimide such as dicyclohexylcarbodiimide (optionally in the presence of an additive such as hydroxybenzotriazole) or a carbodiimide derivative.
- a carbodiimide such as dicyclohexylcarbodiimide (optionally in the presence of an additive such as hydroxybenzotriazole) or a carbodiimide derivative.
- activated substituent group refers to a chemical functional group that generally allows a substitution reaction to take place at the atom to which it is attached.
- the -I group is generally referred to as an activated substituent group because it allows substitution reactions to take place at the aryl carbon.
- Suitable activated substituent groups are well known, and can include halides (chloride, bromide, iodide), activated hydroxyl groups (e.g., triflate, mesylate, and tosylate), and diazonium salts.
- alkyl represents a straight- or branched-chain saturated hydrocarbon, containing 1 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
- exemplary alkyl substituents include, but are not limited to methyl (Me), ethyl (Et), propyl, isopropyl, butyl, isobutyl, t-butyl, and the like.
- alkenyl represents a straight- or branched-chain hydrocarbon, containing one or more carbon-carbon double bonds and having 2 to 10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below.
- alkenyl substituents include, but are not limited to ethenyl, propenyl, butenyl, allyl, pentenyl and the like.
- phenyl refers to a fully unsaturated 6-membered carbocyclic group.
- a "phenyl” group may also be referred to herein as a benzene derivative.
- heteroaryl refers to a group comprising an aromatic monovalent monocyclic, bicyclic, or tricyclic group, containing 5 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more of the substituents described below.
- heteroaryl is also intended to encompass the N-oxide derivative (or N-oxide derivatives, if the heteroaryl group contains more than one nitrogen such that more than one N-oxide derivative may be formed) of the nitrogen-containing heteroaryl groups described herein.
- heteroaryl groups include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, benzo[b]thienyl, naphtho[2,3-b]thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathienyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxyalinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, te
- N-oxide derivatives of heteroaryl groups include, but are not limited to, pyridyl N-oxide, pyrazinyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, triazinyl N-oxide, isoquinolyl N-oxide, and quinolyl N-oxide.
- heteroaryl groups include the following moieties: wherein R is H, alkyl, hydroxyl or is a suitable nitrogen protecting group.
- halide represents fluoro, chloro, bromo or iodo substituents.
- a desired salt may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid, such as glucuronic acid or galacturonic acid, alpha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnamic acid, sulfonic acid, such as
- a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
- suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
- the compounds of the present invention may contain at least one chiral center and may exist as single stereoisomers (e.g., single enantiomers or single diastereomers), any mixture of stereoisomers (e.g., any mixture of enantiomers or diastereomers) or racemic mixtures thereof. It is specifically contemplated that, unless otherwise indicated, all stereoisomers, mixtures and racemates of the present compounds are encompassed within the scope of the present invention.
- stereoisomeric purity refers to the "enantiomeric” purity and/or “diastereomeric” purity of a compound.
- stereoisomerically pure form is meant to encompass those compounds that contain from at least about 95% to at least about 99%, and all values in between, of a single stereoisomer.
- substantially enantiomerically pure as used herein is meant to encompass those compounds that contain from at least about 90% to at least about 95%, and all values in between, of a single stereoisomer.
- diastereomerically pure is meant to encompass those compounds that contain from at least about 95% to at least about 99%, and all values in between, of a single diastereoisomer.
- substantially diastereomerically pure is meant to encompass those compounds that contain from at least about 90% to at least about 95%, and all values in between, of a single diastereoisomer.
- racemic or “racemic mixture,” as used herein, refer to a mixture containing equal amounts of stereoisomeric compounds of opposite configuration.
- a racemic mixture of a compound containing one stereoisomeric center would comprise equal amount of that compound in which the stereoisomeric center is of the (S)- and (R)-configurations.
- enantiomerically enriched is meant to refer to those compositions wherein one stereoisomer of a compound is present in a greater amount than the opposite stereoisomer.
- diastereomerically enriched refers to those compositions wherein one diastereomer of compound is present in amount greater than the opposite diastereomer.
- the compounds of the present invention may be obtained in stereoisomerically pure (i.e., enantiomerically and/or diastereomerically pure) or substantially stereoisomerically pure (i.e., substantially enantiomerically and/or diastereomerically pure) form.
- stereoisomerically pure i.e., enantiomerically and/or diastereomerically pure
- substantially stereoisomerically pure i.e., substantially enantiomerically and/or diastereomerically pure
- Such compounds may be obtained synthetically, according to the procedures described herein using stereoisomerically pure or substantially stereoisomerically pure materials.
- these compounds may be obtained by resolution/separation of mixtures of stereoisomers, including racemic and diastereomeric mixtures, using known procedures.
- Exemplary methods that may be useful for the resolution/separation of stereoisomeric mixtures include derivitation with stereochemical ⁇ pure reagents to form diastereomeric mixtures, chromatographic separation of diastereomeric mixtures, chromatographic separation of enantiomeric mixtures using chiral stationary phases, enzymatic resolution of covalent derivatives, and crystallization/re-crystallization.
- Other useful methods may be found in Enantiomers, Racemates, and Resolutions, J. Jacques, et a!., 1981 , John Wiley and Sons, New York, NY, the disclosure of which is incorporated herein by reference.
- Preferred stereoisomers of the compounds of this invention are described herein. Detailed Description of the Invention
- the compounds of formula I can be prepared from 6-nitroindazole.
- the indazole ring can be substituted at the C-3 position with an R 1 group as described herein, using commonly known reagents and reactions.
- the C-3 position of the indazole ring can be functionalized by reacting 6-nitroindazole with iodine (I 2 ) in the presence of a base such as potassium carbonate (K 2 CO 3 ), and in a solvent such as DMF, to provide 3-iodo-6-nitro-indazole.
- a base such as potassium carbonate (K 2 CO 3 )
- DMF solvent
- the C-3 position of the indazole ring can then be elaborated to a desired R 1 group using known reactions, such as a Suzuki reaction or a Heck reaction.
- the intermediates useful for the preparation of the compounds of formula I may require the use of protecting groups.
- the nucleophilic indazole ring nitrogen (N-1) may require masking through use of a suitable protecting group.
- the substituents on these intermediates are themselves not compatible with the synthetic methods of this invention, the substituents may be protected with suitable protecting groups that are stable to the reaction conditions used in these methods.
- the protecting groups may be removed at a suitable point in the reaction sequence of the method to provide a desired intermediate or target compound. Suitable protecting groups and the methods for protecting and de-protecting different substituents using such suitable protecting groups are well known, examples of which may be found in T. Greene and P. Wuts, supra.
- a suitable nitrogen protecting group, W is one that is stable to the reaction conditions in which the compounds of formula Il are allowed to react with the compounds of formula III to provide the compounds of formula IV. Furthermore, such a protecting group should be chosen so that it can be subsequently removed to provide the compounds of formula I. As indicated above, suitable nitrogen protecting groups are well known, and any nitrogen protecting group that is useful in the methods of preparing the compounds of this invention or may be useful in the protein kinase inhibitory compounds of this invention may be used.
- Exemplary nitrogen protecting groups include silyl, substituted silyl, alkyl ether, substituted alkyl ether, cycloalkyl ether, substituted cycloalkyl ether, alkyl, substituted alkyl, carbamate, urea, amide, imide, enamine, sulfenyl, sulfonyl, nitro, nitroso, oxide, phosphinyl, phosphoryl, silyl, organometallic, borinic acid and boronic acid groups. Examples of each of these groups, methods for protecting nitrogen moieties using these groups and methods for removing these groups from nitrogen moieties are disclosed in T. Greene and P. Wuts, supra.
- suitable nitrogen protecting groups useful as W include, but are not limited to, silyl protecting groups (e.g., SEM: trimethylsilylethoxymethyl, TBDMS: tert-butyldimethylsilyl); alkyl ether protecting groups such as cycloalkyl ethers (e.g., THP: tetrahydropyran); carbamate protecting groups such as alkyloxycarbonyl (e.g., Boc: t-butyloxycarbonyl), aryloxycarbonyl (e.g., Cbz: benzyloxycarbonyl, and FMOC: fluorene-9-methyloxycarbonyl), alkyloxycarbonyl (e.g., methyloxycarbonyl), alkylcarbonyl or arylcarbonyl, substituted alkyl, especially arylalkyl (e.g., trityl (triphenylmethyl), benzyl and substituted benzyl), and the like.
- W is a silyl protecting group (e.g., SEM: trimethylsilylethoxymethyl, TBDMS: tert- butyldimethylsilyl)
- silyl protecting groups may be attached to nitrogen moieties and hydroxyl groups via their silyl chlorides (e.g., SEMCI: trimethylsilylethoxymethyl chloride, TBDMSCI: tert-butyldimethylsilyl chloride) in the presence of a suitable base (e.g., potassium carbonate), catalyst (e.g., 4-dimethylaminopyridine (DMAP)), and solvent (e.g, N,N-dimethyl formamide).
- a suitable base e.g., potassium carbonate
- catalyst e.g., 4-dimethylaminopyridine (DMAP)
- solvent e.g, N,N-dimethyl formamide
- Such silyl protecting groups may be cleaved by exposure of the subject compound to a source of fluoride ions, such as the use of an organic fluoride salt such as a tetraalkylammonium fluoride salt, or an inorganic fluoride salt.
- Suitable fluoride ion sources include, but are not limited to, tetramethylammonium fluoride, tetraethylammonium fluoride, tetrapropylammonium fluoride, tetrabutylammonium fluoride, sodium fluoride, and potassium fluoride.
- silane protecting groups may be cleaved under acidic conditions using organic or mineral acids, with or without the use of a buffering agent.
- suitable acids include, but are not limited to, hydrofluoric acid, hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, and methanesulfonic acid.
- suitable Lewis acids include, but are not limited to, dimethylbromo borane, triphenylmethyl tetrafluoroborate, and certain Pd (II) salts.
- Such silane protecting groups can also be cleaved under basic conditions that employ appropriate organic or inorganic basic compounds.
- such basic compounds include, but are not limited to, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, and potassium hydroxide.
- the cleavage of a silane protecting group may be conducted in an appropriate solvent that is compatible with the specific reaction conditions chosen and will not interfere with the desired transformation.
- suitable solvents are, for example, alkyl esters, alkylaryl esters, aryl esters, alkyl ethers, aryl ethers, alkylaryl esters, cyclic ethers, hydrocarbons, alcohols, halogenated solvents, alkyl nitriles, aryl nitriles, alkyl ketones, aryl ketones, alkylaryl ketones, or non-protic heterocyclic compounds.
- suitable solvents include, but are not limited to, ethyl acetate, isobutyl acetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, dimethoxyethane, diisopropyl ether, chlorobenzene, dimethyl formamide, dimethyl acetamide, propionitrile, butyronitrile, t-amyl alcohol, acetic acid, diethyl ether, methyl-t-butyl ether, diphenyl ether, methylphenyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1 , 4-dioxane, pentane, hexane, heptane, methanol, ethanol, 1-propanol, 2-propanol, t-butanol, n-butanol, 2-butanol, dichloromethane, chloroform, 1 ,
- W is a cyclic ether protecting group (e.g., a tetrahydropyran (THP) group)
- THP tetrahydropyran
- such cyclic ethers may be attached to nitrogen moieties and hydroxy! groups via their enol ethers (e.g., dihydropyran (DHP)) in the presence of a suitable acid (e.g., para-toluenesulfonic acid or methanesulfonic acid), and solvent (e.g., dichloromethane).
- DHP dihydropyran
- Such cyclic ether groups may be cleaved by treating the subject compound with organic or inorganic acids or Lewis acids.
- a particular reagent will depend upon the type of ether present as well as the other reaction conditions.
- suitable reagents include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, para-toluenesulfonic acid, methanesulfonic acid, or Lewis acids such as boron trifluoride etherate.
- solvents that are compatible with the specific reaction conditions chosen and will not interfere with the desired transformation.
- suitable solvents are, for example, alkyl esters, alkylaryl esters, aryl esters, alkyl ethers, aryl ethers, alkylaryl esters, cyclic ethers, hydrocarbons, alcohols, halogenated solvents, alkyl nitriles, aryl nitriles, alkyl ketones, aryl ketones, alkylaryl ketones, or non-protic heterocyclic compounds.
- suitable solvents include, but are not limited to, ethyl acetate, isobutyl acetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, dimethoxyethane, diisopropyl ether, chlorobenzene, dimethyl formamide, dimethyl acetamide, propionitrile, butyronitrile, t-amyl alcohol, acetic acid, diethyl ether, methyl-t-butyl ether, diphenyl ether, methylphenyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1 ,4-dioxane, pentane, hexane, heptane, methanol, ethanol, 1-propanol, 2-propanoI, t-butanol, n-butanol, 2-butanol, dichloromethane, chloroform, 1
- N-1 indazole ring nitrogen Protection of the N-1 indazole ring nitrogen is accomplished by reacting 3-iodo-6- nitroindazole with 3,4-dihydro-2H-pyran and methanesulfonic acid in a solvent, such as DMF, tetrahydrofuran (THF), and methylene chloride (CH 2 CI 2 ) to provide 3-iodo-6-nitro-1- (tetrahydropyran-2-yl)-1 H-indazole.
- a solvent such as DMF, tetrahydrofuran (THF), and methylene chloride (CH 2 CI 2 )
- R 1 is C 1 -C 8 alkyl, -OH, -NO 2 , -CN, -CO 2 H, -0(C 1 -C 8 alkyl), -aryl, -aryl(C r C 8 alkyl), -CO 2 CH 3 , -CONH 2 , -OCH 2 CONH 2 , -NH 2 , -SO 2 NH 2 , haloalkyl, or -O(haloalkyl), may require the use suitable protecting groups.
- Suitable hydroxyl protecting groups that are useful in the present invention include, but are not limited to, alkyl or aryl esters, alkyl silanes, aryl silanes or alkylaryl silanes, alkyl or aryl carbonates, benzyl groups, substituted benzyl groups, ethers, or substituted ethers.
- the various hydroxyl protecting groups can be applied and suitably cleaved utilizing a number of known reaction conditions. The particular conditions used will depend on the particular protecting group as well as the other functional groups contained in the subject compound. Furthermore, suitable conditions include the use of an appropriate solvent that is compatible with the reaction conditions utilized and will not interfere with the desired transformation.
- Suitable solvents useful in applying the various protecting groups and their subsequent removal may include alkyl esters, alkylaryl esters, aryl esters, alkyl ethers, aryl ethers, alkylaryl esters, cyclic ethers, hydrocarbons, alcohols, halogenated solvents, alkyl nitriles, aryl nitriles, alkyl ketones, aryl ketones, alkylaryl ketones, and non-protic heterocyclic compounds.
- suitable solvents include, but are not limited to, ethyl acetate, isobutyl acetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, dimethoxyethane, diisopropyl ether, chlorobenzene, dimethyl formamide, dimethyl acetamide, propionitrile, butyronitrile, t-amyl alcohol, acetic acid, diethyl ether, methyl-t-butyl ether, diphenyl ether, methylphenyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1 ,4-dioxane, pentane, hexane, heptane, methanol, ethanol, 1-propanol, 2-propanol, t-butanol, n-butanol, 2-butanol, dichloromethane, chloroform, 1
- the C-3 position of the indazole ring can be elaborated to a desired R 1 group through a Suzuki or Heck reaction, using the appropriate catalyst, ligand, aryl, heteroaryl and/or olefinic species.
- the Suzuki reaction is a palladium catalyzed coupling reaction in which the reaction of an optionally substituted aryl boronic acid or an optionally substituted heteroaryl boronic acid is coupled with a substituted aryl group or a substituted heteroaryl group, in which the substituents on the aryl group or the heteroaryl group are halide, triflate, or a diazonium salt, which produces a di-aryl species.
- Useful palladium catalysts for the Suzuki reaction includes but are not limited to Pd(C 17 H 14 O) x , Pd(PPh 3 ) 4 ⁇ and [Pd(OAc) 2 ] 3 , and the like.
- a base such as an inorganic base or an organic base (e.g., organic amine) is also required to neutralize the liberated acid.
- organic base e.g., organic amine
- R 1 is a substituted or unsubstituted aryl group, or is a substituted or unsubstituted heteroaryl group
- the compounds of formula I can be prepared by a Suzuki reaction between an optionally substituted aryl or heteroaryl boronic acid and a substituted aryl or heteroaryl group, in which the substituents on the aryl or heteroaryl group are halide, triflate, or a diazonium salt.
- a Heck reaction involves the catalytic coupling of C-C bonds, where a vinylic hydrogen is replaced by a vinyl, aryl, or benzyl group, with the latter being introduced as a halide, diazonium salt, aryl triflate or hypervalent iodo compound.
- R vinyl, aryl, or benzyl
- Palladium in the form of Pd(II) salts or complexes and Pd(O), with 1-5% mole concentration, is the most widely used metal catalyst for these types of reactions.
- a base such as an inorganic base or an organic base (e.g., organic amine) is also required to neutralize the liberated acid.
- Typical catalysts for use in the Heck reaction include but are not limited to Pd(dppf)CI 2 /CH 2 CI 2 , [Pd(OAc) 2 ] 3 , trans-PdCI 2 (CH 3 CN) 2 , Pd(C 17 H 14 O) x , and Pd(0)-phosphine complexes such as Pd(PPh 3 ) 4 and trans-PdCI 2 (PPh 3 ) 2 or in situ catalysts such as Pd(OAc) 2 /PPh 3 , and the like.
- Chelated phosphines with larger bite angles such as Cp 2 Fe(PPh 2 J 2 and Ph 2 P(CH 2 ) 2 .
- PPh 2 are useful with catalysts such as Pd(OAc) 2 , (pi-allyl)Pd complexes, Pd 2 (dba) 3 , Pd(dba) 2 and PdCI 2 , and the like.
- the presence of phosphines "stabilize" these catalysts.
- these types of reactions are conducted in polar aprotic mediums (sigma donor type solvents such as acetonitrile, N,N-dimethyl formamide, dimethyl sulfoxide or dimethylacetamide).
- the reaction time and temperature depend on the nature of the organic halide to be activated, lodo derivatives are more reactive and hence auxiliary ligands (phosphines) may not be required.
- polar solvents such as N,N-dimethyl formamide, dimethylacetamide and N-methylpyrrolidine in combination with sodium acetate as a base are especially beneficial.
- the compounds of formula I can be prepared by a Heck reaction between a compound containing a vinylic hydrogen and a compound containing a vinyl, aryl, or benzyl group which is substituted with a halide, halide, diazonium salt, aryl triflate or hypervalent iodo compound.
- a Heck reaction between 3-iodo-6-nitro-1-(tetrahydropyran-2-yl)-1H-indazole and 2-vinyl pyridine is accomplished by heating these reactants in the presence of a catalyst such as palladium(ll) acetate (Pd(OAc) 2 ), a ligand such as tri-o-tolylphosphine, a suitable base such as N,N-diisopropylethyl-amine, and a solvent such as DMF to provide 6-nitro-3-((E)-2-pyridin-2-yl- vinyl)-1-(tetrahydropyran-2-yl)-1H-indazole.
- a catalyst such as palladium(ll) acetate (Pd(OAc) 2 )
- a ligand such as tri-o-tolylphosphine
- suitable base such as N,N-diisopropylethyl-amine
- solvent such as DMF
- the compounds of formula I contain an indazole ring and phenyl ring that are bridged by a sulfide group.
- Such sulfide linked ring structures are obtained by coupling an indazole derivative which is substituted with an activated substituent group X (compound of formula II) with a thiophenol derivative (compound of formula III).
- Suitable activated substituent groups for X include but are not limited to halides (e.g., chloride, bromide, iodide), hydroxyl derivatives (e.g., triflate, mesylate, and tosylate groups), and diazonium salts.
- Derivatization of the 6-nitroindazole ring compounds described above, with an activated substituent X group can be accomplished by reduction of the 6-nitro group to the 6-amino indazole compound, followed by diazotization, and optionally, displacement of N 2 with a nucleophile such as a halide, water, or aqueous base.
- a nucleophile such as a halide, water, or aqueous base.
- 6-nitroindazole ring compounds can be converted to 6-amino indazole compounds by a reduction.
- the reduction of nitro groups to amino groups are well known.
- Metals, such as Fe (iron), Zn (zinc), Sn (tin) and In (indium) can be used with a H + source to reduce a nitro group to an amino group by a sequence of single electron transfer (SET)/protonation reactions.
- 6-nitro-3-(E)-2-pyridin-2-yl-vinyl)-1-(tetrahydropyran-2-yl)-1H-indazole is reduced to the 6- amino compound by treatment with iron metal in the presence of an aqueous solution of ammonium chloride to provide 6-amino-3-(E)-2-pyridin-2-yl-vinyl)-1-(tetrahydropyran-2-yl)-1 H- indazole.
- Diazotizing reagents useful for converting an amino group to a diazonium salt include but are not limited to sodium nitrite and tert-butyl nitrite. These diazotizing reactions require the presence of a strong acid such as hydrochloric acid to convert the amino group into the diazonium salt.
- Alkali metal halides, such as lithium, sodium and potassium halides are a convenient source of nucleophilic halide anions. Hydroxyl groups are easily converted into triflate, mesylate and tosylate groups using standard procedures.
- the coupling reaction between the compounds of formula Il and the compounds of formula III to provide the compounds of formula IV is accomplished in the presence of a catalyst, a base, and optionally, one or more solvents.
- the catalyst may be either a palladium or a copper catalyst. Methods that use palladium or copper catalysts to couple aryl sulfides to aryl compounds containing an activated substituent X are well known.
- palladium catalysts which are useful in the above coupling reaction include but are not limited to Pd(dppf)CI 2 -CH 2 CI 2 , [Pd(P'-Bu 3 )( ⁇ -Br)] 2 , Pd(PCy 3 ) 2 CI 2 , Pd(P(o-tolyl) 3 ) 2 CI 2 , [Pd(P(OPh-2,4-t- BuJ) 2 CI] 2 , FibreCat® 1007 (PCy 2 -fibre/Pd(OAc) 2 ), FibreCat® 1026 (PCy 2 -fibre/PdCI 2 /CH 3 CN), FibreCat® 1001 (PPh 2 -fibre/Pd(OAc) 2 ), Pd(dppf)CI 2 , Pd(dppb)CI 2 , Pd(d(dppe)CI 2 , Pd(PPh 3 ) 4 , Pd(PPh 3 )CI 2 , and the like
- phosphine ligands are also complexes to the palladium catalyst, for example: Pd 2 (dba) 3 complexed to a phospine ligand such as 2-(tert-butyl 2 - phosphino)biphenyl; Pd(dba) 2 complexed to P(t-Bu) 3 ; Pd(OAc) 2 complexed to (o-biphenyl)P(t- Bu) 2 ; and Pd 2 (dba) 3 complexed to (o-biphenyl)P(t-Cy) 2 .
- Pd 2 (dba) 3 complexed to a phospine ligand such as 2-(tert-butyl 2 - phosphino)biphenyl
- Pd(dba) 2 complexed to P(t-Bu) 3 Pd(OAc) 2 complexed to (o-biphenyl)P(t- Bu) 2
- Copper catalysts which are useful in the above coupling reaction include those catalysts in which the copper is complexed with one or more ligands, including but not limited to Cul/ethylene glycol complex; CuBr/DBU complex, Cu(PPh 3 )Br; and Cu(PPh 3 )Br additionally complexed to 1 ,10-phenanthroline or neocuproine (e.g., Cu(phen) (PPh 3 )Br and Cu(neocup)(PPh 3 )Br, respectively), and the like.
- ligands including but not limited to Cul/ethylene glycol complex
- CuBr/DBU complex Cu(PPh 3 )Br
- Cu(PPh 3 )Br additionally complexed to 1 ,10-phenanthroline or neocuproine (e.g., Cu(phen) (PPh 3 )Br and Cu(neocup)(PPh 3 )Br, respectively), and the like.
- Bases which are useful in the above coupling reaction include but are not limited to potassium carbonate, sodium carbonate, cesium carbonate, sodium tert-butoxide, potassium tert- butoxide, potassium phenoxide, triethylamine, and the like, or mixtures thereof.
- Solvents may be used in such coupling reactions including but not limited to toluene, xylenes, diglyme, tetrahydrofuran, dimethylethyleneglycol, and the like, or mixtures thereof.
- the activated substituent X in the compounds of formula III should be such that it provides sufficient reactivity to react with the compounds of formula Il to provide the compounds of formula IV.
- Compounds of formula III that contain such activated substituents may be prepared, isolated and/or purified, and subsequently reacted with the compounds of formula II.
- compounds of formula III with suitable activated substituents may be prepared and further reacted without isolation or further purification with the compounds of formula Il to afford the compounds of formula IV.
- suitable activated substituent groups for X are halogens (e.g., Cl, Br, and I); derivatized hydroxyl groups (e.g., triflate, mesylate, and tosylate); and diazonium salts.
- 6-iodo-3-((E)-2-pyridin-2-yl-vinyl)-1-(tetrahydropyroan-2-yl)-1 H-indazole is reacted with a catalytic amount of Pd(dppf)CI 2 -CH 2 CI 2 , cesium carbonate and 2-mercapto-N-methylbenzamide in DMF at 80 0 C to provide 6-(2-mercapto-N-methylbenzamide)-3-((E)-2-pyridin-2-yI-vinyl)-1- (tetrahydropyroan-2-yl)-1H-indazole.
- suitable reagents and reaction conditions for deprotecting the N-1 indazole ring nitrogen group, W are well known.
- suitable reagents include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, para-toluenesulfonic acid, methanesulfonic acid, or Lewis acids such as boron trifluoride etherate. These reactions may be conducted in solvents that are compatible with the specific reaction conditions chosen and will not interfere with the desired transformation.
- palladium removal can be accomplished using 10% cysteine-silica as discussed in a U.S. provisional patent application entitled Methods for the Removal of Heavy Metals, attorney docket number PC032215, filed on November 1, 2004, and is hereby incorporated by reference in its entirety. Palladium removal can also be combined with conditions that allow crystallization of the synthesized compounds in various polymorphic forms.
- Form IV when a compound of formula I is prepared where R1 is 2-vinyl pyridine, R2 is methyl, and R3 are each hydrogen, the polymorphic form designated as Form IV can be produced by refluxing in tetrahydrofuran, N,N-dimethyl formamide, and methanol, followed by the addition of acetic acid and xylenes.
- the formation and characterization of Form IV, as well as other polymorphs, is discussed in more detail in a U.S.
- 2,2'-dithiosalicylic acid is treated with reagents such as thionyl chloride or oxalyl chloride in the presence of a suitable base such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, a trialkylamine, triethylamine for example, or a heteroaromatic base such as pyridine to provide the 2,2'-dithiosaIicylic acid dichloride.
- a suitable base such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, a trialkylamine, triethylamine for example, or a heteroaromatic base such as pyridine
- a suitable base such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, a trialkylamine, triethylamine for example, or a heteroaromatic base such as
- reaction conditions chosen will depend on the specific subject compound and reagents chosen.
- Other suitably functionalized thiophenol compounds may be generated using appropriately functionalized disulfides as starting materials.
- the resulting sulfides (compounds of formula III) should be protected from light to prevent disulfide formation.
- These sulfides may be isolated and further reacted with the compounds of formula Il or they may be reacted with the compounds of formula Il without isolation or further purification.
- Another synthetic route to the compounds of formula I is provided in the Examples section below.
- indazole compounds of formula I which are useful as modulators and/or inhibitors of protein kinases. These compounds, prepared by the methods of the present invention, are useful as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.
- Infrared spectra were recorded on a Perkin-Elmer FT-IR Spectrometer as neat oils, as KBr pellets, or as CDCI 3 solutions, and when reported are in wave numbers (cm "1 ).
- the mass spectra were obtained using LC/MS or APCI. All melting points are uncorrected.AII final products had greater than 95% purity (by HPLC at wavelengths of 220nm and 254nm).
- DMF means N,N-dimethyl formamide
- THF means tetrahydrofuran
- Et means ethyl
- Ac means acetyl
- Me means methyl
- Ph means phenyl
- HI means hydrochloric acid
- EtOAc means ethyl acetate
- Na 2 CO 3 means sodium carbonate
- NaHCO 3 means sodium hydrogen carbonate (sodium bicarbonate)
- NaOH means sodium hydroxide
- Na 2 S 2 O 3 means sodium thiosulfate
- NaCI means sodium chloride
- Et 3 N means triethylamine
- H 2 O means water
- KOH means potassium hydroxide
- K 2 CO 3 means potassium carbonate
- MeOH means methanol
- i-PrOAc means isopropyl acetate
- MgSO 4 means isopropyl acetate
- MgSO 4 means isopropyl acetate
- MgSO 4 means isoprop
- 6-Nitroindazole 45.08 Kg is dissolved in DMF (228 Kg) and powdered potassium carbonate (77 Kg) is added while the solution temperate is maintained at ⁇ 3O 0 C.
- a solution of iodine (123 Kg) dissolved in DMF (100 Kg) is added over 5 to 6 hours while the reaction temperature is maintained ⁇ 35 0 C. (Caution: the reaction is exothermic).
- the reaction mixture is agitated for 1 to 5 hours at 22 0 C (until the reaction is complete by HPLC).
- the mixture is then added to a solution of sodium thiosulfate (68 Kg) and potassium carbonate (0.46 Kg) dissolved in water (455 Kg) while the solution temperature is maintained ⁇ 30 0 C.
- the mixture is agitated for
- 3-iodo-6-nitroindazole (74.6 Kg) is dissolved in methylene chloride (306 Kg) and THF (211 L), and methanesulfonic acid (3.0 Kg) is carefully added. (Caution: residual sodium bicarbonate may cause CO 2 to be evolved. Monitor the pressure in the reactor).
- a solution of DHP (55 Kg) in methylene chloride (97 Kg) is added over 5 to 6 hours while the reaction temperature is maintained at ⁇ 22 0 C. The mixture is agitated at 22 0 C for 2 to 6 hours (until the reaction is complete by HPLC).
- the mixture is then carefully added to an aqueous solution of 10% NaHCO 3 (37 Kg of NaHCO 3 dissolved in 370 Kg water) while the solution temperature is maintained at 22 0 C. (Caution: CO 2 is evolved. Monitor the pressure in the reactor).
- the mixture is agitated for 1 hour at 22 0 C and the layers separated.
- the organic layer is washed with an aqueous solution of 10% NaCI (407 Kg) and the layers separated.
- the organic layer is concentrated at 55 0 C and atmospheric pressure to cut the volume to half (ca. 500 L), then under reduced pressure to remove the remaining solvents.
- the concentrate (ca.138 L) is co- evaporated with acetonitrile (1 x 224 Kg, 1 x 75 Kg, 1 x 60 Kg) at 55 0 C under reduced pressure until the final volume is ca. 80 L.
- the resulting slurry is diluted with acetonitrile (60 Kg) and is agitated for 8 hours at -5 0 C.
- the slurry is filtered, and the solids are rinsed with cold acetonitrile (15 Kg).
- the solids are dried at room temperature under reduced pressure to provide 77.6 Kg of 3-iodo-6-nitro-1-(tetrahydropyran-2-yl)-1H-indazole (80.5% yield with a purity of 95% by HPLC).
- Example 3 Preparation of 6-nitro-3-((E)-2-pyridin-2-yl-vinylV1-(tetrahvdropyran-2-yl)-1 H-indazole
- 3-iodo-6-nitro-1-(tetrahydropyran-2-yl)-1 H-indazole (77 Kg) is added to a solution of 2- vinyl pyridine (31 Kg), N,N-diisopropylethylamine (51 Kg), and tri-o-tolylphosphine (5.414 Kg) in DMF (163 Kg).
- Pd(OAc) 2 (1.503 Kg) is added and the mixture is agitated for 12 to 18 hours at 100 0 C (until the reaction is complete by HPLC). The mixture is then cooled to 45 0 C and isopropanol (248 Kg) is added.
- the mixture is agitated for 30 minutes at 45 0 C, diluted with water (1,238 L), and the mixture is agitated at 22 0 C for 1 to 2 hours.
- the resulting slurry is filtered, rinsed with water (77 L), and the solids are combined with isopropanol (388 Kg).
- the mixture is agitated for 30 to 90 minutes at 55 0 C, then for 30 to 90 minutes at 1O 0 C, filtered, and the solids are washed with cold (ca. 10 0 C) isopropanol (2 x 30 L).
- 6-nitro-3-(E)-2-pyridin-2-yl-vinyl)-1-(tetrahydropyran-2-yl)-1H-indazole (61.4 Kg) is dissolved in an aqueous solution of ammonium chloride (71.4 Kg of NH 4 CI in 257 Kg water) and ethanol (244 Kg) is added. Iron powder (39 Kg) is added and the mixture is agitated for 2 to 8 hours at 50 0 C (until the reaction is complete by HPLC). (Add more iron powder (ca. 9.8 Kg) if the reaction is not complete after 8 hours). The mixture is then cooled to 22 0 C and THF (1 ,086 Kg) is added.
- the mixture is agitated for 1 hour at 22 0 C, and filtered through diatomaceous earth (ca. 5 Kg).
- the cake is rinsed with THF (214 Kg), and the filtrate is concentrated at 50 0 C under reduced pressure to a volume of ca. 305 L.
- the concentrate is cooled to 22 0 C, diluted with water (603 Kg), and agitated at 22 0 C for 1 hour.
- the mixture is filtered, rinsed with heptanes (62 Kg), dried in a vacuum oven for 24 to 48 hours (50 0 C and 25 mm Hg) to provide 51.5 Kg of 6-amino-3-((E)- 2-pyridin-2-yl-vinyl)-1-(tetrahydropyran-2-yl)-1 H-indazole (91.8% yield with a purity of 95% by HPLC).
- Methylene chloride (4 L) at O 0 C is added over 10 minutes to the diazonium salt solution at O 0 C, and a solution of potassium iodide (1.062 Kg) and iodine (396 g) dissolved in water (3 L) at O 0 C is added over 1.5 hours.
- the reaction mixture is agitated for 3 hours at O 0 C (until complete by HPLC).
- the mixture is then poured into a solution of 20% aqueous sodium hydrogen sulfite (2 Kg sodium thiosulfate in 10 L water) and methylene chloride (4 L) at O 0 C, agitated, and the layers separated.
- the aqueous layer is extracted with methylene chloride (2 x 4 L) at O 0 C and combined.
- a solution of 28% aqueous ammonium hydroxide (1 L) and water (2 L) is added, and the mixture is agitated for 30 minutes at 10 0 C, and allowed to settle for 24 hours to afford a clear phase separation.
- the layers are separated and the aqueous layer is extracted with methylene chloride (2 x 6 L).
- the combined organic layers (ca. 35 L) are loaded onto a glass fritted column (7 in. ID and 20 in.
- 2-mercapto-N-methylbenzamide (17.2 Kg) is added and the mixtu re is agitated for 4 to 16 hours at 8O 0 C (until the reaction is complete by HPLC).
- the mixture is then cooled to 22 0 C and ethyl acetate (412 Kg) is added and the mixture is agitated for 1 hour at 22 0 C.
- Water (686 Kg) is added and the mixture is agitated at 22 0 C for 2 hours.
- the mixture is f ⁇ Itered and the solids are washed with ethyl acetate (62 Kg), water (137 Kg), and ethyl acetate (62 Kg).
- the solids are dissolved in THF (93.3 Kg) and methylene chloride (686 Kg), and the solution is eluted through a column containing sand (25 Kg, at the bottom of the column), Florisil (453 Kg, in the middle of the column) and sand (97.8 Kg, on the top of the column), with a solution of THF (15.4 Kg) and methylene chloride (113 Kg) 35 0 C, followed by five portions of THF (31 Kg) and methylene chloride (226 Kg) 35 0 C.
- the fractions containing the product are collected and concentrated under reduced pressure to a volume of ca. 103 L.
- Ethyl acetate (20 ⁇ Kg) is added, and the solution is concentrated under reduced pressure to a volume of ca. 172 L.
- Water (69 g) is added and the solution is agitated for 2 hours at 22 0 C.
- the solids are filtered, washed with ethyl acetate (62 Kg), and dried in a vacuum oven for 24 to 48 hours (55 0 C and 25 mm Hg) to provide 20.2 Kg of 6-(2-mercapto-N-methylbenzamide)-3-((E)-2-pyridin-2-yl-vinyl)-1 -(tetrahydropyroan-2-yl)-1 H- indazole as a light brown solid (54% yield with a purity of 98%).
- the mixture is agitated for 30 minutes at 65 0 C, cooled to 3 0 C, and the solids are filtered and washed with cold ethyl acetate (61 Kg). This sequence removes any residual methanol since trace amounts of methanol may prevent the formation of the desired polymorph form III during the neutralization step.
- the solids are transferred to a reactor, diluted with ethyl acetate (82 Kg), agitated for 3 minutes at O 0 C, and neutralized by addition of 5% aqueous sodium bicarbonate solution (175 Kg) (aqueous phase pH ⁇ 7). Caution: carbon dioxide is evolved.
- the slurry is agitated for 2 hours at 22 0 C and a sample is withdrawn (60 ml_) to check the pH and to test for polymorph form. If the DSC indicates that the conversion of polymorph form Vl to polymorph form III ( ⁇ Vz ethyl acetate solvate) is not complete, continue the agitation at 22 0 C and check DSC every 4 hours until the formation of polymorph form III is confirmed. A long period of agitation (ca. 16 hours) may be required for the complete polymorph conversion.
- Example 7 If 6-(2-mercapto-N-methylbenzamide)-3-((E)-2-pyridin-2-yl-vinyl)-1-H-indazc>le from Example 7 is an off-white solid (polymorph III), then proceed with Example 8a.
- 2.423 Kg is added to methanol (75 L) and the mixture is agitated for 1.5 hours at 1 5 to 25 0 C.
- the slurry is filtered, and the solids are washed with methanol (12.5 L) and dried in a vacuum oven at room temperature for 24 hours.
- the dried solids are added to a solution of scetic acid (100 L) at ca. 35 0 C, and the mixture is agitated for 45 minutes at ca. 35 0 C until a clear solution is obtained.
- the solution is cooled to room temperature and activated carbon (Darco G- ⁇ 0, 2.5 Kg) is added.
- the mixture is stirred at room temperature for 2 to 3 hours, filtered through Celite (3.0 Kg), and the filtrate is concentrated at 7O 0 C under reduced pressure to a volume of 25 L.
- the solution is cooled to 25 0 C and xylenes (25 L) are added.
- the solution is heated to 7O 0 C, and concentrated at 7O 0 C under reduced pressure to a volume of 25 L. This procedure is repeated four times until solids appear.
- 2,2'-dithiosalicylic acid (421 g) is dissolved in toluene (1.7 L) and thionyl chloride (212 mL) and DMF (7 ml_) are added, and the mixture is agitated for 20 hours at 82 0 C. The mixture is then cooled to 7O 0 C and hexanes (2 L) are added. Further cooling to 10 0 C provides a solid precipitate.
- 2,2'-dithiosalicylic acid dichloride (90 g) dissolved in THF (500 mL) is added to a solution of 2 M methyl amine in THF (655 mL) in over 40 minutes at 0 0 C, and agitated at room temperature for 16 hours. The mixture is then diluted with water (200 mL) and the resulting slurry is filtered. The solids are washed with water (2x 50 mL), dried in a vacuum oven for 16 hours (55 0 C and 25 mm Hg) to provide 50 g of 2,2'-dithio-N-methylbenzamide (65% yield with a purity of 86% by HPLC).
- 2,2'-dithio-N-methylbenzamide (967.2 g) is suspended in ethanol (9.0 L) and cooled to O 0 C.
- Sodium borohydride (253 g) is added in portions over 4 hours, and the mixture is agitated for 5 hours at O 0 C.
- 3 M hydrochloric acid (3.15 L) is then added to the mixture in over 15 minutes which adjusted the pH to 1.73.
- the mixture is concentrated under reduced pressure and 45 0 C to remove the ethanol.
- the concentrate is diluted with ethyl acetate (8 L) and water (4 L) and agitated for 20 minutes. The layers are allowed to separate (30 minutes), and the aqueous layer is removed. Solids and an emulsion remain in the organic layer.
- 2-(3-lodo-1H-indazol-6-ylsulfanyl)-N-methyl-benzamide (239.19 g), 2-vinyIpyridine (75.7 mL, 702 Mmol), Pd(OAc) 2 (6.56 g), P(O-ToI) 3 (23.12 g), Proton Sponge (187.82 g), LiBr (314.59 g), and DMA (3.1 L, 3.5 mL/g) were added to a 5 L 3-neck flask, equipped with a mechanical stirrer and a temperature probe. The mixture was degassed three times by alternately connecting to house vacuum and nitrogen.
- the mixture was then heated to 110 0 C in one hour and the temperature was maintained at 110 0 C for 24 hours, at which time all of the 2-(3-lodo-1 H-indazol- 6-ylsulfanyl)-N-methyl-benzamide was consumed (HPLC).
- HPLC 2-(3-lodo-1 H-indazol- 6-ylsulfanyl)-N-methyl-benzamide was consumed.
- the mixture was transferred to a 22 L extractor and followed by the addition of 5.5 L of CH 2 CI 2 , 5.5 L of water and 275 mL of 37% aqueous HCI. After agitation and partitioning, the organic phase was extracted twice with 2.0 L of water and 100 mL of 37% HCI. At this stage, the organic phase (HPLC) did not contain any significant amount of the final product (HPLC), and was discarded.
- An aqueous solution of NaHSO 3 was prepared by adding 13.6 g of solid NaHSO 3 into 250 mL of Dl water with strong stirring. 6-iodoindazole (30.0 g), followed by DMF (60 mL) were added to a 500 mL three-neck flask that was fitted with a mechanical stirrer, a temperature probe, and a 100 mL dropping funnel. After the stirring had begun, the flask was immersed in an ice/water bath. After 30 mintues, KOH was added in one portion, and the resulting mixture was stirred for an additional 30 minutes. A solution of 54.3g of I 2 in 55 mL of DMF (total volume was 71 mL) was added to the dropping funnel and the run-in started.
- N-1 THP 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole (355 g) was suspended in 2,485 ml_ of methanol, after which p-toluenesulfonic acid monohydrate (718 g) was added. The mixture was then heated to 65 0 C (hard reflux) for 4 hours under argon while the reaction was monitored by HPLC (gluco method). Heating continued until less than 1% of the N-1 THP protected starting material persisted. The heating was then removed and the reaction was cooled to room temperature.
- the solid was filtered and the wet cake was washed with methanol (2 volumes, 710 mL) then the solids were rinsed with ethyl acetate (2 volumes, 710 mL).
- the wet cake was transferred to a reactor containing sodium bicarbonate (126.84 g), deionized water (1800 mL), and ethyl acetate (975 mL), which was then stirred for 2 hours at 2O 0 C.
- the solids were filtered and washed with 5 volumes of deionized water (1800 mL), then with 2 volumes of ethyl acetate (760 mL), and then dried in a vacuum oven at 40 0 C for 16 hours.
- the mixture was heated to 100 0 C and the temperature was maintained at 100 0 C overnight, at which time all the starting material was consumed (HPLC). After cooling, the mixture was poured into 800 ml_ of saturated NaHCO 3 and 400 ml_ of EtOAc was added. The mixture was stirred for half an hour at which time a thick precipitate formed. The solid was filtered off and the filtrate was allowed to partition. After partitioning, the aqueous layer was extracted twice with 300 ml_ of EtOAc. The combined organic layers were washed twice with water, dried over MgSO 4 and concentrated. The residue crystallized on standing at room temperature. The solid was treated with 20 ml_ of EtOAc and filtered.
- the residue was pre- adsorbed onto silica gel and subjected to flash chromatography, using hexanes/EtOAc (2:1 , 1 :1 , 1 :2, 1 :3) to yield 21.77 g of the final product.
- 2-(3-lodo-1 H-indazol-6-ylsulfanyl)-N-methyl-benzamide (2.30 g), 2-ethynylpyridine (0.25 mL), Pd(PPh 3 J 2 CI 2 (128 mg), CuI (64 mg), (/-Pr) 2 NEt (0.50 mL), and N,N-dimethylformamide (15 mL) were added to a 50 mL 3-neck flask, equipped with a stirring bar and a temperature probe. The mixture was degassed by alternately connecting to house vacuum and nitrogen three times, and heated at 66 0 C for one hour.
- the mixture was filtered through a medium sintered glass fritted funnel, and the cake was washed with a solution of 500 mL of DMA and 500 mL of THF.
- the cake was further washed with 2.0 L of THF and the filtrate was collected into a separate flask.
- the volatile parts in the latter filtrate were removed in vacuo and the residue was combined with the main filtrate.
- the combined filtrate was recharged back into the 12 L flask, followed by 800 g of 10% cysteine-silica.
- the flask was equipped with a mechanical stirrer and stirred over the weekend at room temperature.
- the mixture was then filtered through a medium sintered glass fritted funnel and the silica was washed with a mixture of solvents of 500 ml.
- the cake was charged to a 5 L 3-neck flask, followed by 1.6 L of THF and 160 mL of DMF.
- the flask was equipped with a mechanical stirrer, a reflux condenser and the mixture was heated at reflux for 8 hours. After cooling overnight, the mixture was filtered through sharkskin filter paper and sucked dry.
- the cake was charged to a 5 L 3-neck flask and 1.6 L of MeOH was added.
- the flask was equipped with a mechanical stirrer, a water condenser and the contents were heated at reflux for 6 hours. After cooling overnight, the mixture was filtered through sharkskin filter paper and sucked dry.
- the cake was dissolved into 1.6 L of HOAc with the assistance of gentle heating in the water bath of a rotary evaporator.
- the solution was filtered through #3 filter paper and the total volume of the filtrate was reduced to ⁇ 500 mL in volume on the rotary evaporator at 60 °C/60 mmHg.
- the bulk of the mixture remained a yellow solution and a small amount of precipitate formed.
- To the flask was charged 500 mL of xylenes (precipitate formed) and the total volume was reduced to -500 mL in volume on the rotary evaporator at 60°C/60 mmHg. The process was repeated two more times. After cooling, the mixture was filtered, the cake was washed with 500 mL of xylenes and sucked dry. The cake was transferred to a glass dish and further dried at 80°C/27 inch vacuum overnight.
- the cake was off-white in color and weighed 108.38g.
- X-ray powder diffraction analysis indicated that a crystalline form was present, which was characterized as Form IV by a powder X- ray diffraction pattern comprising peaks at the following approximate diffraction angles (20): 8.9, 12.0, 14.6, 15.2, 15.7, 17.8, 19.2, 20.5, 21.6, 23.2, 24.2, 24.8, 26.2, and 27.5.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0517921-1A BRPI0517921A (pt) | 2004-11-02 | 2005-10-21 | métodos para preparar compostos de indazol |
MX2007003603A MX2007003603A (es) | 2004-11-02 | 2005-10-21 | Metodos para preparar compuestos de indazol. |
AU2005300311A AU2005300311A1 (en) | 2004-11-02 | 2005-10-21 | Methods for preparing indazole compounds |
CA002586176A CA2586176A1 (fr) | 2004-11-02 | 2005-10-21 | Methodes de preparation de composes d'indazole |
RU2007114112/04A RU2007114112A (ru) | 2004-11-02 | 2005-10-21 | Способ получения индазольных соединений |
EP05796299A EP1809625A1 (fr) | 2004-11-02 | 2005-10-21 | Methodes de preparation de composes d'indazole |
JP2007538538A JP2008518901A (ja) | 2004-11-02 | 2005-10-21 | インダゾール化合物を調製するための方法 |
IL182096A IL182096A0 (en) | 2004-11-02 | 2007-03-21 | Methods for preparing indazole compounds |
NO20072747A NO20072747L (no) | 2004-11-02 | 2007-05-30 | Fremgangsmate for fremstilling av indazolforbindelser |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62457504P | 2004-11-02 | 2004-11-02 | |
US60/624,575 | 2004-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006048745A1 true WO2006048745A1 (fr) | 2006-05-11 |
Family
ID=35528034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/003300 WO2006048745A1 (fr) | 2004-11-02 | 2005-10-21 | Methodes de preparation de composes d'indazole |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1809625A1 (fr) |
JP (1) | JP2008518901A (fr) |
KR (1) | KR20070058689A (fr) |
CN (1) | CN101044138A (fr) |
AR (1) | AR051753A1 (fr) |
AU (1) | AU2005300311A1 (fr) |
BR (1) | BRPI0517921A (fr) |
CA (1) | CA2586176A1 (fr) |
IL (1) | IL182096A0 (fr) |
MX (1) | MX2007003603A (fr) |
NO (1) | NO20072747L (fr) |
RU (1) | RU2007114112A (fr) |
TW (1) | TW200614990A (fr) |
WO (1) | WO2006048745A1 (fr) |
ZA (1) | ZA200702317B (fr) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044045A1 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
WO2008044041A1 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
EP2163544A1 (fr) * | 2008-09-16 | 2010-03-17 | Pfizer, Inc. | Méthodes de préparation de composés d' indazole |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
WO2013046133A1 (fr) | 2011-09-30 | 2013-04-04 | Pfizer Inc. | Compositions pharmaceutiques de n-méthyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl-benzamide |
WO2013068909A1 (fr) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-méthyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide pour le traitement de la leucémie myéloïde chronique |
CN103570696A (zh) * | 2013-11-06 | 2014-02-12 | 湖南欧亚生物有限公司 | 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用 |
US8791140B2 (en) | 2007-04-05 | 2014-07-29 | Pfizer Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
EP2792360A1 (fr) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV |
WO2015067224A1 (fr) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Sels de 6-[2- (méthylcarbamoyl) phénylsulfanyl]-3-e-[2-(pyridin-2-yl) éthanyl]indazole |
EP3127900A4 (fr) * | 2014-03-31 | 2017-02-22 | Senju Pharmaceutical Co., Ltd. | Dérivé alcynylique d'indazole et son utilisation |
US9580406B2 (en) | 2015-04-28 | 2017-02-28 | Signa S.A. De C.V. | Processes for the preparation of axitinib |
EP3498734A1 (fr) | 2014-02-04 | 2019-06-19 | Pfizer Inc | Combinaison d'un antagoniste pd-1 et d'un inhibiteur vegfr pour le traitement du cancer |
WO2020128893A1 (fr) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Traitements combinés de cancer comprenant un agoniste de tlr |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
WO2020212253A1 (fr) | 2019-04-18 | 2020-10-22 | Synthon B.V. | Procédé de préparation d'axitinib, procédé de purification de l'intermédiaire 2-((3-iodo-1h-indazol-6-yl)thio)-n-méthylbenzamide, procédé de purification d'axitinib par l'intermédiaire du sel d'axitinib hcl, forme solide du sel d'axitinib hcl |
US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
US11274154B2 (en) | 2016-10-06 | 2022-03-15 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
WO2023166420A1 (fr) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Anticorps multispécifiques et leurs utilisations |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103387565B (zh) * | 2013-07-29 | 2014-10-29 | 苏州明锐医药科技有限公司 | 阿西替尼的制备方法 |
CN104072484B (zh) * | 2014-07-07 | 2016-07-06 | 渤海大学 | 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用 |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
CN112209861A (zh) * | 2019-07-11 | 2021-01-12 | 鲁南制药集团股份有限公司 | 一种阿昔替尼中间体化合物及其制备方法 |
CN112442010B (zh) * | 2019-08-30 | 2023-10-03 | 润佳(苏州)医药科技有限公司 | 一类前药化合物及其在治疗癌症方面的应用 |
CN111440102B (zh) * | 2020-04-26 | 2022-02-15 | 大连凯飞化学股份有限公司 | 一种二硫代二苯甲酰胺类化合物的制备方法 |
CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001002369A2 (fr) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci |
WO2004056806A1 (fr) * | 2002-12-19 | 2004-07-08 | Pfizer Inc. | Composes de 2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques |
US20040192653A1 (en) * | 2003-03-03 | 2004-09-30 | Mark Munson | P38 inhibitors and methods of use thereof |
WO2005094823A1 (fr) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | INHIBITEUR DE Flt-3 |
-
2005
- 2005-10-21 KR KR1020077009804A patent/KR20070058689A/ko not_active Ceased
- 2005-10-21 CA CA002586176A patent/CA2586176A1/fr not_active Abandoned
- 2005-10-21 MX MX2007003603A patent/MX2007003603A/es unknown
- 2005-10-21 BR BRPI0517921-1A patent/BRPI0517921A/pt not_active IP Right Cessation
- 2005-10-21 RU RU2007114112/04A patent/RU2007114112A/ru not_active Application Discontinuation
- 2005-10-21 EP EP05796299A patent/EP1809625A1/fr not_active Withdrawn
- 2005-10-21 CN CNA2005800361530A patent/CN101044138A/zh active Pending
- 2005-10-21 JP JP2007538538A patent/JP2008518901A/ja not_active Withdrawn
- 2005-10-21 WO PCT/IB2005/003300 patent/WO2006048745A1/fr active Application Filing
- 2005-10-21 AU AU2005300311A patent/AU2005300311A1/en not_active Abandoned
- 2005-11-01 TW TW094138224A patent/TW200614990A/zh unknown
- 2005-11-01 AR ARP050104567A patent/AR051753A1/es not_active Application Discontinuation
-
2007
- 2007-03-20 ZA ZA200702317A patent/ZA200702317B/xx unknown
- 2007-03-21 IL IL182096A patent/IL182096A0/en unknown
- 2007-05-30 NO NO20072747A patent/NO20072747L/no not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001002369A2 (fr) * | 1999-07-02 | 2001-01-11 | Agouron Pharmaceuticals, Inc. | Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci |
WO2004056806A1 (fr) * | 2002-12-19 | 2004-07-08 | Pfizer Inc. | Composes de 2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques |
US20040192653A1 (en) * | 2003-03-03 | 2004-09-30 | Mark Munson | P38 inhibitors and methods of use thereof |
WO2005094823A1 (fr) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | INHIBITEUR DE Flt-3 |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044041A1 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
WO2008044045A1 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
EP4249063A2 (fr) | 2007-04-05 | 2023-09-27 | Pfizer Products Inc. | Formes cristallines de 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole utiles pour le traitement d'une croissance cellulaire anormale chez des mammiferes |
EP4074702A1 (fr) | 2007-04-05 | 2022-10-19 | Pfizer Products Inc. | Formes cristallines de 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole utiles pour le traitement d'une croissance cellulaire anormale chez des mammiferes |
US8791140B2 (en) | 2007-04-05 | 2014-07-29 | Pfizer Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
JP2014193900A (ja) * | 2007-04-05 | 2014-10-09 | Pfizer Products Inc | Vegf−r阻害剤の新規結晶形 |
EP3252047A2 (fr) | 2007-04-05 | 2017-12-06 | Pfizer Products Inc. | Formes cristallines de 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole utiles pour le traitement d'une croissance cellulaire anormale chez des mammiferes |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US8431694B1 (en) * | 2007-10-25 | 2013-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
EP2163544A1 (fr) * | 2008-09-16 | 2010-03-17 | Pfizer, Inc. | Méthodes de préparation de composés d' indazole |
WO2013046133A1 (fr) | 2011-09-30 | 2013-04-04 | Pfizer Inc. | Compositions pharmaceutiques de n-méthyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl-benzamide |
US9205078B2 (en) | 2011-11-11 | 2015-12-08 | Pfizer Inc. | N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
WO2013068909A1 (fr) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-méthyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide pour le traitement de la leucémie myéloïde chronique |
EP2792360A1 (fr) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV |
CN103570696B (zh) * | 2013-11-06 | 2016-02-24 | 湖南欧亚生物有限公司 | 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用 |
CN103570696A (zh) * | 2013-11-06 | 2014-02-12 | 湖南欧亚生物有限公司 | 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用 |
WO2015067224A1 (fr) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Sels de 6-[2- (méthylcarbamoyl) phénylsulfanyl]-3-e-[2-(pyridin-2-yl) éthanyl]indazole |
EP3498734A1 (fr) | 2014-02-04 | 2019-06-19 | Pfizer Inc | Combinaison d'un antagoniste pd-1 et d'un inhibiteur vegfr pour le traitement du cancer |
EP3971209A1 (fr) | 2014-02-04 | 2022-03-23 | Pfizer Inc. | Combinaison d'un antagoniste pd-1 et d'un inhibiteur vegfr pour le traitement du cancer |
US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
CN106458920A (zh) * | 2014-03-31 | 2017-02-22 | 千寿制药株式会社 | 炔基吲唑衍生物及其用途 |
RU2667486C2 (ru) * | 2014-03-31 | 2018-09-20 | Сэндзю Фармацевтикал Ко., Лтд. | Производное алкинилиндазола и его применение |
JPWO2015152117A1 (ja) * | 2014-03-31 | 2017-04-13 | 千寿製薬株式会社 | アルキニルインダゾール誘導体及びその用途 |
US9617222B1 (en) | 2014-03-31 | 2017-04-11 | Senju Pharmaceutical Co., Ltd. | Alkynyl indazole derivative and use thereof |
EP3127900A4 (fr) * | 2014-03-31 | 2017-02-22 | Senju Pharmaceutical Co., Ltd. | Dérivé alcynylique d'indazole et son utilisation |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
US9580406B2 (en) | 2015-04-28 | 2017-02-28 | Signa S.A. De C.V. | Processes for the preparation of axitinib |
US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
US11274154B2 (en) | 2016-10-06 | 2022-03-15 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
WO2020128893A1 (fr) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Traitements combinés de cancer comprenant un agoniste de tlr |
WO2020212253A1 (fr) | 2019-04-18 | 2020-10-22 | Synthon B.V. | Procédé de préparation d'axitinib, procédé de purification de l'intermédiaire 2-((3-iodo-1h-indazol-6-yl)thio)-n-méthylbenzamide, procédé de purification d'axitinib par l'intermédiaire du sel d'axitinib hcl, forme solide du sel d'axitinib hcl |
WO2023166420A1 (fr) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Anticorps multispécifiques et leurs utilisations |
WO2023166418A2 (fr) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Anticorps multispécifiques et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
CN101044138A (zh) | 2007-09-26 |
MX2007003603A (es) | 2007-05-21 |
BRPI0517921A (pt) | 2008-10-21 |
ZA200702317B (en) | 2008-09-25 |
AU2005300311A1 (en) | 2006-05-11 |
CA2586176A1 (fr) | 2006-05-11 |
RU2007114112A (ru) | 2008-12-10 |
NO20072747L (no) | 2007-07-31 |
EP1809625A1 (fr) | 2007-07-25 |
TW200614990A (en) | 2006-05-16 |
KR20070058689A (ko) | 2007-06-08 |
AR051753A1 (es) | 2007-02-07 |
IL182096A0 (en) | 2007-07-24 |
JP2008518901A (ja) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006048745A1 (fr) | Methodes de preparation de composes d'indazole | |
TWI658042B (zh) | 雜環化合物的合成 | |
EP2190804B1 (fr) | Procédé et intermédiaires de préparation d'inhibiteurs de l'intégrase | |
CN101094836A (zh) | 制备吲唑化合物的方法 | |
US20070203196A1 (en) | Methods of preparing indazole compounds | |
US7232910B2 (en) | Methods of preparing indazole compounds | |
EP3325485B1 (fr) | Procédés de préparation de dérivés de benzodiazépine cytotoxiques | |
CN102712585A (zh) | 中性内肽酶抑制剂中间体和其制备方法 | |
EP1140933B1 (fr) | Procede de preparation de derives de deaza-adenosine n6-substitues | |
JP5017101B2 (ja) | 不斉四置換炭素原子含有化合物の製法 | |
JP5787893B2 (ja) | ビフェニルイミダゾール化合物の調製方法 | |
US5817823A (en) | Method for synthesizing 2-substituted imidazoles | |
EP4196131A1 (fr) | Synthèse de nucléotides fluorés | |
EP1814859A2 (fr) | Procedes de preparation de composes indazole | |
JP7315805B1 (ja) | 単環ピリジン誘導体の合成中間体の製造方法 | |
EP2163544A1 (fr) | Méthodes de préparation de composés d' indazole | |
CN118401509A (zh) | 制备(2R,3S)-2-(苯并[d]咪唑丙基)哌啶-3-醇衍生物的方法 | |
JPH0812670A (ja) | 新規なピロリジン誘導体 | |
CA2584617A1 (fr) | Procede servant a produire un derive de benzo[c]phenanthridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 182096 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003603 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005300311 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2384/DELNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005300311 Country of ref document: AU Date of ref document: 20051021 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005300311 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580036153.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007538538 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500938 Country of ref document: PH Ref document number: 07042929 Country of ref document: CO Ref document number: 1020077009804 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2586176 Country of ref document: CA Ref document number: 554867 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005796299 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007114112 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005796299 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0517921 Country of ref document: BR |